Ms. Onel practices FDA law with a primary focus on regulatory issues involving medical devices, foods, dietary supplements, over-the-counter drugs, cosmetics and consumer products. She regularly advises international and domestic manufacturers, distributors, and researchers on market entry strategies, labeling and promotional activities, regulatory compliance, recalls and field corrections, and enforcement defense. Ms. Onel assists clients with the preparation of FDA submissions, including 510(k) premarket notifications, premarket approval applications (PMAs), food additive petitions, GRAS self-affirmations and notifications, food contact notifications, new dietary ingredient notifications, and adverse event reports. Ms. Onel’s experience includes representing clients before the U.S. Food and Drug Administration, the Federal Trade Commission, the U.S. Department of Agriculture, the Bureau of Alcohol, Tobacco, and Firearms, the National Advertising Division of the Better Business Bureaus, and similar international and state bodies.
Ms. Onel’s practice also includes FDA due diligence investigations and advising companies and private equity/venture capital investors on transactional matters involving life science company acquisition, divestment and capital growth as well as supplier contracts and clinical research agreements.
Ms. Onel regularly speaks and writes on FDA issues including medical device software, food regulation and dietary supplement/functional food. She has written articles and chapters in compilations published by the Food and Drug Law Institute, the Regulatory Affairs Professionals Society, the Medical Device & Diagnostic Industry, and others. Ms. Onel is also co-editor of the PLI treatise, “Medical Devices Law and Regulation Answer Book” (5th edition).
Prior to joining KKB, Ms. Onel was Chair of the FDA Practice at a global law firm.
Former Chair, Food, Cosmetics and Nutraceuticals Committee, ABA Section of Sciences & Technology Law (2012-2015)
Former Co-Chair, FDLI Medical Devices Committee (2012-2015)
Former FDA Counsel, Neurotechnology Industry Organization (NIO) (2008-2015)
UVA Law Class Manager, Annual Giving Program, 2005-2009
Former Chair, FDLI Update Editorial Advisory Board
Member, Food and Drug Law Institute (FDLI) and Regulatory Affairs Professionals Society (RAPS)
Quoted in Washington Lawyer, “What are Some of the Top Trends in Food Law?” (October 2017).
Quoted in Bloomberg Law/BNA Medical Devices Law & Industry Report, “When does Changing a Medical Device Trigger FDA Rules?” (September 13, 2017).
Quoted in Washington Post Magazine, “The Battle over Essure” (July 30, 2017).
Listed in “The Best Lawyers in America” directory for FDA Law, US News and World Report, 2015-2019
Listed in Washington D.C. Super Lawyers, Thomson Reuters, 2015-2017
Ms. Onel’s recent speaking engagements include the following:
“Development of Medical Devices: Best Practices for Safeguarding Your IP and FDA Rights,” FDLI On-Demand Webinar, November 2017.
“Investigational Device Exemptions (IDE) and the Practice of Medicine,” Children’s Hospitals Pediatric Research Alliance, Boston, MA, October 2017.
“Improving Commerce for Economic Growth, “ Keynote Speaker at Central American regional conference on trade facilitation and best practices to improve entry of food, drugs, and medical devices into Honduras. Invited by U.S. State Department. Conference supported by the U.S. Embassy, the Foreign Agricultural Service, the U.S. Commercial Service, American Chamber of Commerce, and USAID. Tegucigalpa, Honduras. May 2017.
“3D Printing: Regulatory, Reimbursement and Product Risk Considerations,” AdvaMed MedTech 2016 Annual Conference, Minneapolis, MN, October 2016.
“Food Safety Modernization Act: The Future of Food Litigation,” Inter-American Law Review Symposium, University of Miami Law School, February 2015.
“Advertising Enforcement,” FDLI Food Week 2015, Moderator, February 2015.
“FDA’s 510(k) Premarket Notification Program: What It Is and Where It’s Going,” Center for Professional Advancement (CfPA), January 2015.
First Annual EU Nutrition and Consumer Law Workshop Association of Corporate Counsel (Utah) and Stoel Rives, September 2014.
FDLI Annual Conference, Moderator, Breakout Session for Medical Device Center Directors, Washington, D.C., April 2014.
“Compliance and Liability Issues: Latest Developments,” FDLI Medical Devices Conference: Key Legal and Regulatory Developments, Washington, D.C., February 2014.
“Best Practices by Promotional Review Teams: Ensuring Compliant and Effective Promotion,” FDLI Advertising and Promotion Conference, Washington, D.C., September 2013.
“Eighth Annual Neurotech Investing & Partnering Conference,” NeuroInsights, San Francisco, CA, May 2013.
“Regulation of Medical Food and Nutritionals in the European Union, China, and the United States,” K&L Gates Webinar, April 2013.
“Health-Related Foods: Claims, Marketing, Labeling and Expectations,” 2012 RAPS Conference – The Regulatory Convergence, Seattle, WA, October 2012.
“What Medical Device Stakeholders Are and Should Be Talking About,” FDLI Medical Device Regulation and Litigation Conference, Washington, D.C., June 2012.
“Seventh Annual Neurotech Industry Investing and Partnering Conference,” NeuroInsights, Boston, MA, May 2012.
“Navigating Regulatory Pathways in Neurology and Psychiatry,” Sixth Annual Neurotech Industry Investing and Partnering Conference, NeuroInsights, San Francisco, CA, May 2011.
“Medical Device Regulatory Compliance,” 3-day Conference for CfPA, New Brunswick, NJ, April 2011.
“FDA’s 510(k): Premarket Notification Program: What It Is and Where It’s Going,” CfPA Webinar, March 2011.
“FDA’s MenaFlex Decision and Its Potential Impact on the Device Clearance Process,” OCTANe, Irvine, CA, February 2011.
“Navigating Regulatory Pathways in Neurology and Psychiatry,” Fifth Annual Neurotech Industry Investing and Partnering Conference, NeuroInsights, Boston, MA, May 2010.
“FDA Update,” NIO Policy Tour, Washington, D.C., March 2010.
“Clinical Investigations: Investigational Device Exemption (IDE), Institutional Review Boards (IRs) and Informed Consent,” FDA Commissioner’s Fellowship Program, FDA Campus, Silver Spring, MD, January 2010.
“FDA: Is There Any Hope?” Fourth Annual Life Sciences CEO Summit Sponsored by Morgenthaler Ventures, San Francisco, CA, November 2009.
Ms. Onel’s recent publications include the following:
Books and Chapters
Medical Devices Law and Regulation Answer Book (PLI 5th Edition 2016), Treatise Co-Editor and Chapter Author.
“Cosmetic Regulation Revisited,” Food and Drug Law and Regulation (FDLI 3rd Ed, 2015).
“Where the ‘App’ World and FDA Collide: Current Status of the FDA’s Regulation of Medical Device Software and Mobile Medical Apps,” Inside the Minds – Recent Developments in Food and Drug Law (Thomson Reuter 2014).
Welcomed New Developments in FDA’s Regulation of Digital Health Products, FDA Alert, August 2017.
21st Century Cures Act Provides (Some) Clarity on FDA’s Regulation of Software, FDLI Update Medical Devices Issue, March/April 2017.
President Obama Signs Federal GMO Law, Preempts Vermont Law. Food, Drugs, Medical Devices and Cosmetics (FDA) Alert, 8 August 2016.
The Future of Medical Device Manufacturing is Here: FDA Issues Draft Guidance on Technical Considerations for 3D Printing. Food, Drugs, Medical Devices and Cosmetics (FDA) Alert, 29 July 2016.
How American Eat: Unveiling of the New Nutrition Facts Label. Food, Drugs, Medical Devices and Cosmetics (FDA) Alert, 21 June 2016.
U.S. FDA Finalizes Medical Foods Guidance. Food, Drugs, Medical Devices and Cosmetics (FDA) Alert, 1 June 2016.
Vermont Act 120 and Beyond: Genetically Engineered Food, Where Are We Now? Food, Drugs, Medical Devices and Cosmetics (FDA) Alert, 11 May 2016.
FDA’s Evolving Policy Toward Health IT, Medical Apps, and Low Risk Devices. Food, Drugs, Medical Devices and Cosmetics (FDA) Alert, 11 March 2015.